Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Necuparanib |
| Synonyms | |
| Therapy Description |
Necuparanib (M402) is heparan sulfate mimetic that inhibits multiple heparin-binding factors, which may result in inhibition of tumor growth and metastasis (PMID: 21698156, PMID: 29158367, PMID: 30401693). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Necuparanib | M402 | Necuparanib (M402) is heparan sulfate mimetic that inhibits multiple heparin-binding factors, which may result in inhibition of tumor growth and metastasis (PMID: 21698156, PMID: 29158367, PMID: 30401693). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01621243 | Phase Ib/II | Gemcitabine + Nab-paclitaxel Necuparanib | M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | Terminated | USA | CAN | 0 |